Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mayne Pharma Group Ltd.

www.maynepharma.com

Latest From Mayne Pharma Group Ltd.

Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny

Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.

Deals M & A

Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Regulation United States

Mayne Cannot Revive US Antifungals Patent

A late disclosure of interest for its parent group should not prevent Merck Sharp & Dohme from knocking down Mayne Pharma’s US antifungals formulation patent, the US Court of Appeals has ruled.

 

Intellectual Property United States

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
    • OTC, Consumer
  • Services
  • Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • HalcyGen Pharmaceuticals Ltd.
  • FH Faulding & Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Mayne Pharma Group Ltd.
  • Senior Management
  • Scott Richards, CEO, Managing Dir.
    Nick Freeman, CFO
    Ilana Stancovski, PhD, CSO
    Peter Paltoglou, Chief Dev. Officer & Head, M&A
  • Contact Info
  • Mayne Pharma Group Ltd.
    Phone: (61) 8 8209 2666
    1538 Main North Rd.
    Salisbury South, 5106
    Australia
UsernamePublicRestriction

Register